Kadcyla breast cancer drug

Kadcyla breast cancer drug

C022/5704 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 50.0MB

Downloadable file size: 1.4MB

Price image Pricing

Please login to use the price calculator

This image is part of the feature B B C


Restrictions: Editorial use only

Caption: Kadcyla breast cancer drug. Bottle containing the anti-cancer drug trastuzumab emtansine, marketed under the name Kadcyla, in powder form for intravenous infusion. This drug is an antibody-drug conjugate (ADC) with an antibody linked to a drug that kills the cancer cells targeted by the antibody. In this case, the conjugate is of trastuzumab (Herceptin) linked to the cytotoxic chemical mertansine (DM1). Herceptin targets the HER2 receptor in breast cancer.

Release details: Model release not required. Property release not required.

Keywords: 100 mg, adc, antibody drug conjugate, antibody-drug conjugate, bottle, breast cancer, cancer treatment, cut out, cut outs, cut-out, cut-outs, cutout, cutouts, cytotoxic, dm1, drug, drugs, healthcare, herceptin, infusion, intravenous, kadcyla, medical, medication, medicine, mertansine, no-one, nobody, oncological, oncology, pharmaceutic, pharmaceutical, pharmacological, pharmacology, powder, prescription, still life, still-life, trastuzumab emtansine, treatment, white background

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.